We are excited to announce the launch of Magnolia Analytics, our highly innovative, technology-enabled service solution. This platform, which was developed in close collaboration with several large U.S. hospital systems, enables the robust quantification of clinical and economic value created by significantly reducing blood culture contamination to improve sepsis testing accuracy. With the launch of Magnolia Analytics, Magnolia Medical Technologies exclusively provides hospitals and healthcare systems with an end-to-end, software-driven solution to support sustained achievement of near-zero blood culture contamination rates. Read the full press release here: https://lnkd.in/gYJ2f-fA
Magnolia Medical Technologies
Medical Equipment Manufacturing
Seattle, Washington 3,324 followers
Partnering with you to achieve near-zero blood culture contamination rates with Steripath
About us
Magnolia Medical Technologies is on a Mission to ZERO®. Today, we offer healthcare institutions a solution to some of their biggest hidden problems – contamination leading to misdiagnosis of bloodstream infections, including sepsis, which can lead to unnecessary and prolonged antibiotic therapy, and false-positive CLABSIs. Tomorrow, we aspire to create a world free of in-vitro diagnostic errors where rapid, accurate test results improve the lives of patients and providers alike. We know that setting new standards of care is a journey enabled by purposeful innovation, partnerships, and perseverance. As the first step of our journey, we have successfully developed and proven our evidence-based technology platform, Steripath, which we’ve coupled with unparalleled support to change clinical practices and prevent unnecessary patient harm as well as system-wide costs associated with the misdiagnosis of sepsis. Our mission is further enabled by reducing false-positive CLABSIs and leveraging our extensive intellectual property portfolio – consisting of over 100 issued method, apparatus, and design patents and 70+ patent applications pending – to address other important sources of diagnostic error that are harmful to patients and costly to hospitals.
- Website
-
https://magnolia-medical.com?utm_source=linkedin&utm_medium=social&utm_campaign=mmt_linkedin_bio_12052023
External link for Magnolia Medical Technologies
- Industry
- Medical Equipment Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Seattle, Washington
- Type
- Privately Held
- Founded
- 2006
- Specialties
- Healthcare, Hospital, Emergency Departments, Antimicrobial Stewardship, Nursing, Medical Reimbursement, Sepsis Prevention, Accurate Blood Testing, Medical Devices, Hospital Reimbursement, Hospital, Medical Technology, Healthcare Technology, Blood Culture Collection, and Infectious Disease Prevention
Locations
-
Primary
Get directions
220 W Mercer St
Suite 100
Seattle, Washington 98119, US
Employees at Magnolia Medical Technologies
Updates
-
🏳️🌈 Happy Pride from Magnolia Medical Technologies! 🏳️🌈 In June (and every other month of the year), we stand with the LGBTQ+ community in celebrating love, diversity, and inclusion for all. At Magnolia Medical Technologies, we believe that everyone deserves to be their authentic selves and to be treated with respect and dignity in the workplace and out. We are committed to creating an inclusive environment for our employees, customers, patients, and community. Join us in celebrating Pride and promoting equality and acceptance for all.
-
Stop by our booth 921 at ASM Microbe from June 14-16! Photographed in our booth (left) is Dr. Paul Goldenbaum, PhD. Dr. Goldenbaum is a Fellow of the American Academy of Microbiology, President of Texas Microbiology Consultants, LLC, and a member of the Magnolia Medical Technologies Medical and Scientific Advisory Board. Learn more about Dr. Goldenbaum and his contributions into blood culture technology by visiting https://lnkd.in/gHDUkFm3
-
-
We're exhibiting at ASM Microbe 2024 in Atlanta, June 14-16! Stop by booth 921 to learn how reducing blood culture contamination, which contributes to a misdiagnosis of sepsis and unnecessary administration of antibiotics like Vancomycin, proves to be one of the most effective methods in preventing multi-drug resistant organisms (MDROs) and avoiding antibiotic-related infections like Clostridioides difficile Infection (CDI). #ASMMicrobe2024 #Microbiology #ScienceConnection
-
-
Thank you #APIC24 for a terrific week!
-
-
Magnolia Medical Technologies reposted this
#APIC24 kicked off today with inspiring educational sessions, heartfelt accounts of how infection prevention changes lives, tons of networking and some super fun exhibitor swag. My most favorite swag of the day, this bag… 🦠🙌❤️
-
-
We're exhibiting at #APIC24 this year in San Antonio, Texas! Join us in booth 1301 from Monday, June 3 - Wednesday, June 5 to learn more about evidence-based solutions to reduce your blood culture contamination rates. We will also be joining BD in booth 1227 to showcase our Steripath®Micro device, offered exclusively with BD Vacutainer® UltraTouch™ Push-Button Blood Collection Set to provide additional benefits.
-
-
We're exhibiting at #NTI2024! Stop by booth 1748 today and tomorrow, May 21-22, to learn more about evidence-based techniques and technologies to reduce blood culture contamination.
-
-
Jacqueline Duda, Sepsis Survivor, Greg Bullington, CEO and Co-Founder of Magnolia Medical Technologies, and Kathy Lester, Legislative Attorney, meeting with Congressional Stakeholders on key patient safety initiatives that reduce the risk of sepsis misdiagnosis and support antimicrobial stewardship efforts.
-
-
We're exhibiting at #NTI2024! Stop by booth 1748 from May 21-22 to learn more about evidence-based techniques and technologies to reduce blood culture contamination. AACN (American Association of Critical-Care Nurses)
-